The BRD2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma A-549 cell line, designed for studying the functional role of the bromodomain-containing protein 2 (BRD2) gene. BRD2 is an epigenetic reader that recognizes acetylated lysine residues on histone H4, acting as a transcriptional regulator of genes critical for cell cycle progression. Disruption of BRD2 in this polyclonal population provides a loss-of-function model to investigate BRD2-dependent gene activation in a physiologically relevant cancer cell context.
The parental A-549 cell line was established from the lung tissue of a 58-year-old male with adenocarcinoma and is widely used as a model of human lung adenocarcinoma, including studies of oncogenic signaling and therapeutic resistance. These adherent epithelial carcinoma cells retain key features of the tumor microenvironment, making them an appropriate host for evaluating BRD2-dependent proliferation pathways. The polyclonal knockout population maintains the genetic heterogeneity of the original cell line, allowing assessment of BRD2 disruption across a mixed genetic background.
At the molecular level, BRD2 functions as a chromatin adaptor that specifically binds acetylated histone H4 through its tandem bromodomains, thereby recruiting the Mediator complex and RNA polymerase II to activate transcription of immediate-early and cell cycle genes. BRD2 functions downstream of acetylated H4 and CDK9-mediated transcriptional regulation, and it is implicated in E2F1-dependent gene expression programs. Key downstream targets include CCND1 and MYC, which encode proteins that drive the G1/S transition. BRD2 also interacts with the related BET family members BRD3 and BRD4, forming part of a regulatory network controlling proliferative gene expression. Knockout of BRD2 disrupts the recruitment of transcriptional machinery to promoters such as the CCND1 promoter, leading to attenuated expression of cell cycle regulators.
In the A-549 lung adenocarcinoma model, BRD2 is involved in sustaining the oncogenic transcriptional program, and its disruption through CRISPR/Cas9 editing impairs the activation of proliferation-associated genes. This polyclonal knockout cell population therefore serves as a valuable tool to dissect the BRD2-dependent branch of BET protein-mediated transcription, particularly in the context of resistance to BET bromodomain inhibitors. By comparing wild-type and knockout cells, researchers can assess the contribution of BRD2 to cell viability, cell cycle progression, and the transcriptional landscape of lung cancer cells.
These knockout cells are suitable for a range of experimental workflows, including Western blotting to confirm BRD2 loss, RT-qPCR to quantify downstream targets CCND1 and MYC, and chromatin immunoprecipitation (ChIP)-qPCR to examine acetylated H4 occupancy at target gene promoters. Functional assays such as cell viability, cell cycle analysis by flow cytometry, and BET inhibitor dose-response curves can be employed to evaluate the phenotypic consequences of BRD2 disruption. The polyclonal nature makes this model particularly useful for population-level studies of gene function, drug screening, and resistance mechanism investigation in lung adenocarcinoma. For further technical details, please contact Ascent Research.
